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Abstract
Background: Cryptococcus neoformans, a basidiomycetous yeast, is a fungal pathogen that can colonize the lungs
of humans causing pneumonia and fungal meningitis in severely immunocompromised individuals. Recent studies
have implied that the antifungal drug fluconazole (FLC) can induce oxidative stress in C. neoformans by increasing
the production of reactive oxygen species (ROS), as presence of the antioxidant ascorbic acid (AA) could reverse the
inhibitory effects of FLC on C. neoformans. However, in Candida albicans, AA has been shown to stimulate the
expression of genes essential for ergosterol biosynthesis. Hence, the contribution of ROS in FLC-mediated growth
inhibition remains unclear.
Results: In order to determine whether counteracting ROS generated by FLC in C. neoformans can contribute to
diminishing inhibitory effects of FLC, we tested three other antioxidants in addition to AA, namely, pyrrolidine
dithiocarbamate (PDTC), retinoic acid (RA), and glutathione (GSH). Our data confirm that there is an increase in ROS
in the presence of FLC in C. neoformans. Importantly, all four antioxidants reversed FLC-mediated growth inhibition
of C. neoformans to various extents. We further verified the involvement of increased ROS in FLC-mediated growth
inhibition by determining that ROS-scavenging proteins, metallothioneins (CMT1 and CMT2), contribute to growth
recovery by PDTC and AA during treatment with FLC.
Conclusion: Our study suggests that ROS contributes to FLC-mediated growth inhibition and points to a complex
nature of antioxidant-mediated growth rescue in the presence of FLC.
Keywords: Antifungal treatment, Antioxidants, ROS, Metallothionein

Background
Eukaryotic pathogens, including pathogenic fungi are an
important cause of death in immunocompromised
patients and can colonize immunocompetent individuals
[1]. Cryptococcal meningitis caused by Cryptococcus
neoformans is the leading cause of fungal central nervous
system infection in the world, especially among persons
suffering from HIV/AIDS [2, 3]. According to CDC
reports, annually one million global cases of cryptococcal
infections occur, accounting for up to 600,000 mortalities and about one-third of all AIDS-associated deaths.
Despite the severity of cryptococcosis, unfortunately
current treatments for cryptococcal infections are inadequate. A main barrier to establishment of an effective
* Correspondence: Srikripa.Chandrasekaran@furman.edu
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antifungal drug therapy is increased drug resistance in
fungi [4–6].
Compared to other anti-cryptococcal drugs, fluconazole (FLC) is the more affordable and less toxic alternative, which is most commonly prescribed in geographic
locations where cryptococcosis is most prevalent [7, 8].
FLC is the drug of choice for moderate pulmonary infections. For central nervous system infections, a combination of more expensive fungicidal drugs amphotericin B
and flucytosine are administered [9, 10]; however, the
combination of these two drugs produces more toxic
side effects for the host.
A well-established mechanism of action of FLC is the
inhibition of Erg11, which is one of the key enzymes
participating in the synthesis of ergosterol, an important
component of the plasma membrane [11]. One factor
that contributes to failure of FLC-based therapy is the
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development of drug resistance. FLC resistance in C.
neoformans occurs primarily via development of aneuploid
cells with elevated levels of Erg11, which prevents diminishment of ergosterol [12]. Other causes for FLC resistance
in pathogenic fungi include accumulation of mutations in
ERG11 [13] and via drug efflux pumps [14, 15]. Importantly, the mechanisms through which FLC leads to formation of aneuploid and FLC resistant cells remain largely
uncharacterized.
While diminishment of ergosterol is a well-documented
cause of FLC-mediated growth inhibition of C. neoformans,
additional possible effects of FLC on C. neoformans cells
have been proposed. FLC treatment has been shown to
cause an increase in reactive oxygen species (ROS) in Candida albicans [16–18] and most recently in C. neoformans
[19]. ROS are molecules with unpaired, highly reactive electrons called free radicals, generated during basic cellular
processes, or due to external stress-inducing conditions,
including environmental pollutants, foreign compounds
such as drugs or chemicals, and exposure to X-rays [20].
Free radicals are highly reactive and unstable and excessive
amounts of ROS are known to cause cell damage and trigger apoptosis. Generation of high amounts of free radicals
can be harmful to biological macromolecules, as it can
cause modification of DNA bases [21], lipid peroxidation,
and protein carbonylation [22] leading to damage due to
oxidative stress. Some examples of ROS include hydroxyl
radicals, hydroxide anion radicals, singlet oxygen, hydrogen
peroxide, hypochlorite, nitric oxide radicals, and peroxynitrite radicals. FLC-mediated increase in ROS could contribute towards oxidative stress in C. neoformans. Consistent
with FLC-triggered ROS contributing to growth inhibition,
co-treatment of C. neoformans cells with FLC and the antioxidant ascorbic acid (AA) was shown to partially rescue C.
neoformans cells from FLC-mediated growth inhibition
[19]. Similarly, co-treatment of C. albicans cells with the
anti-fungal drug miconazole and a synthetic antioxidant,
pyrrolidine dithiocarbamate (PDTC), has been shown to
increase the Minimal Inhibitory Concentration (MIC) of
miconazole [18]. These studies suggest an additional effect
of anti-fungal azole drugs on pathogenic fungi, which is
inducing oxidative stress via an increase in ROS content.
Interestingly, treatment of C. albicans with AA has
been shown to increase expression of the gene UPC2,
which is involved in regulating ergosterol biosynthesis
[23, 24]. This finding suggests that AA might be functioning indirectly to regulate ergosterol levels, which is
by counteracting FLC-mediated inhibition of ergosterol
biosynthesis. Hence, whether ROS increase triggered by
FLC contributes to growth inhibition elicited by FLC remains unclear.
The metal copper has been shown to be essential for
virulence of C. neoformans [25]. Lack of a copper transporter, CTR4, led to reduced virulence in cryptococcosis
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models in mice [26]. During infection by C. neoformans,
copper acquisition and increased copper levels is essential for melanin formation, which confers virulence to C.
neoformans [27]. While elevated copper is essential
during infection, increased copper can be toxic as it
contributes to increased production of ROS, due to its
participation in oxidation and reduction reactions [28].
To counteract harmful effects of copper, C. neoformans
increases expression of metallothionein genes, CMT1
and CMT2, which bind to and sequester copper [29].
Previous studies have shown that C. neoformans mutants
lacking metallothionein genes exhibit attenuated virulence [30] and show an increased sensitivity to FLC [19].
These findings suggest that Cmt1 and Cmt2 proteins
allow for reversal of some of the harmful effects of ROS
generated in the presence of FLC.
The purpose of this study was to perform a more
rigorous test to determine if ROS plays a role in influencing sensitivity to FLC in C. neoformans. In order to determine whether it is the antioxidant properties of AA
that caused rescue of C. neoformans growth inhibition,
we tested three alternative known antioxidants for their
ability to reverse the effects of FLC on the wild type as
well as on metallothionein deficient mutants. Our data
suggest that treatment with FLC leads to increase of
ROS and this oxidative stress may further contribute to
FLC-mediated growth inhibition. Furthermore, this study
suggests that lowering ROS is not the only contributing
factor to the antioxidant-mediated growth rescue and
points to the complex nature of the physiological effects
of FLC.

Results
We wished to determine whether antioxidants with diverse
chemical structures and modes of action could alleviate
FLC-mediated growth inhibition of C. neoformans. In
addition to AA that has been previously shown to reduce
growth inhibition in the presence of FLC in C. neoformans
[19], we tested three chemically unrelated antioxidants: pyrrolidinedithiocarbamate (PDTC), retinoic acid (RA), and a
reduced form of glutathione (GSH). The concentrations of
AA, PDTC, and GSH were established based on previous
studies [18, 19, 31]. The concentration of RA was established as the smallest concentration that rescued growth of
C. neoformans cells in the presence of hydrogen peroxide
(as later indicated in Fig. 3a). Growth of cells on plates with
media supplemented with the respective amounts of the
antioxidants and lacking FLC was not inhibited as compared to the control YPD media (as indicated in Fig. 2b).
As shown in Fig. 1a, in the presence of 32 μg/ml FLC, cell
growth was significantly inhibited, although single colonies
of cells that were likely resistant to FLC were observed. Cotreatment of cells with both FLC and any of the four antioxidants led to rescue of growth. While RA, AA and PDTC
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Fig. 1 PDTC, RA, AA and GSH reverse growth inhibitory effects caused by FLC. a 10,000 cells of Cryptococcus neoformans wild type strain (H99)
were spread on YPD semi-solid media (Control) or YPD media supplemented with FLC at 32 μg/mL alone or with addition of tested antioxidant
compounds as indicated. Growth inhibition was observed in the presence of FLC and restored growth was observed to various degrees in the
presence of antioxidants at 48 h after plating. The presence of Ascorbic Acid (AA) at 10 mM, Retinoic Acid (RA) at 1 mM, and pyrrolidine
dithiocarbonate (PDTC) at 10 μM led to the greatest growth rescue while glutathione (GSH) at 10 mM showed marginalized recovery from FLC
treatment. b Cells were treated with the chemicals as indicated in a, except in liquid cultures at room temperature. (250 C) for 16 h. Cells treated
with FLC at 32 μg/mL became clustered and multi-budded (depicted by arrows) indicative of compromised cytokinesis. Wild type morphology of
cells incubated in the presence of FLC and the antioxidants suggests that the antioxidants rescued cells from cytokinesis defects caused by FLC. c
Graph showing distribution of cell aggregates in population of cells treated as in b. Addition of an antioxidant (especially, PDTC, RA, and AA)
reduced the number of cell aggregates. Bars indicate 20 μm

showed a robust reversal of FLC-mediated growth inhibition, GSH showed only a modest rescue of growth.
It has been previously demonstrated that treatment of C.
neoformans with FLC causes cytokinesis defects, visible as a
multi-budded phenotype [32]. In order to determine
whether the antioxidants can reverse the multi-budded
phenotype resulting from FLC treatment, we treated C.
neoformans cells for 16 h with either 32 μg/ml FLC alone or
FLC and an antioxidant (either RA at 1 mM, AA at 10 mM,
PDTC at 10 μM, or GSH at 10 mM). As shown in Fig. 1b,
cells treated with FLC alone exhibited a multi-budded
phenotype indicative of a cytokinesis defect, consistent with
previous studies (Fig. 1b, arrows). When cells were cotreated with FLC and either AA, RA, PDTC, or GSH, cell

morphology was similar to that of the control sample and
no significant multi-budded phenotype was observed
(Fig. 1b). Thus, the ability of tested antioxidants to rescue
C. neoformans cells from FLC-mediated growth inhibition
correlated with the ability of each of the antioxidants to
reduce the multi-budded morphology of cells resulting
from FLC treatment. In addition to morphological defects,
C. neoformans cells exhibited clumping phenotype in the
presence of 32 μg/ml FLC. As represented in Fig. 1c, cell
aggregates were drastically reduced in the presence of AA,
RA, PDTC, or GSH. These findings suggest that the multibudded phenotype and cell aggregation resulting from FLC
treatment is at least partially caused by the increase of ROS,
based on the ability of various antioxidants to reverse these
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phenotypes. Interestingly, while GSH could rescue FLCinduced morphological growth defects, as shown in Fig. 1b,
co-treatment of cells with FLC at 32 μg/ml and GSH at 10
mM led to only a modest rescue of growth, in contrast to
addition of AA, RA, or PDTC, as shown in Fig. 1a. These
findings suggest that the tested anti-oxidants reverse the
effects of FLC through mechanisms that may not be
identical.
Copper levels are increased during C. neoformans
infection and the increased copper aids C. neoformans
virulence, while also contributing to an increase in ROS
[25, 30]. Metallothionein proteins (Cmt1 and Cmt2),
whose levels increase in response to copper, have been
implicated in lowering ROS by sequestering heavy
metals such as copper [33]. Since it has been shown that
C. neoformans mutants lacking metallothioneins are
more sensitive to FLC [19], we tested whether metallothioneins are required for antioxidant-mediated
growth rescue in the presence of FLC. We carried out a
serial dilution assay where we spotted wild type, cmt1Δ,
cmt2Δ, or cmt1/2Δ mutants as a series of 10-fold diluted
cell cultures. As shown in Fig. 2a, all the strains grew
equally well on a control YPD medium, while on YPD
medium supplemented with FLC (32 μg/ml) all strains
were significantly inhibited. However, growth of wild
type was robustly rescued when cells were grown on
YPD medium supplemented with FLC and RA (Fig. 2a),
Growth rescue of the wild type was less evident in the
presence of AA, or PDTC, and it was minimal in the
presence of GSH. Compared to wild type cells, growth
of the metallothionein mutants could not be rescued to
the same extent when grown in YPD medium supplemented with FLC and PDTC, AA, RA, or GSH. Consistently, both wild type and cmt mutant strains showed
maximum rescue from FLC inhibition by RA (Fig. 2a).
This finding suggests that metallothionein proteins are
necessary for the effective growth rescue by antioxidants
when cells are treated with FLC.
To further test whether treatment of wild type vs metallothionein mutant strains (cmt1Δ, cmt2Δ and cmt1/
2Δ) results in change in sensitivity to FLC, we carried
out a disc diffusion assay, which allowed us to compare
the effects of increasing amounts of FLC. We plated 2 ×
106 cells of either wild type (H99) or metallothionein
mutants on YPD semisolid medium and we placed on
the surface of the medium a control disc and 3 discs
containing 25, 50, or 100 μg of FLC. As shown in Fig. 2b,
all three metallothionein mutant strains exhibited higher
sensitivity to FLC, as indicated by larger zones of inhibition surrounding the discs containing FLC, as compared
to wild type strain. We also utilized the disc diffusion
assays to examine the effects of antioxidants on the
sensitivity of metallothionein mutant strains to FLC. As
indicated in Fig. 2b, and graphed in Fig. 2c (based on
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discs containing 100 micrograms of FLC), wild type
strain (H99) exhibited a significant recovery from FLCmediated growth inhibition in the presence of AA, RA,
PDTC, and GSH with PDTC appearing as most potent.
In contrast, for all three metallothionein mutants, cmt1Δ,
cmt2Δ, or cmt1/2Δ, the recovery from FLC mediated inhibition in the presence of PDTC was less significant as compared to the wild type (Fig. 2c). The cmt1/2Δ double
mutant was unable to significantly recover from FLCmediated growth inhibition in the presence of AA (Fig. 2b,
c). In the presence of RA and GSH, all metallothionein mutants could recover from growth inhibition caused by FLC
(Fig. 2b, c). These findings suggest that the antioxidants
tested may function in different ways to reverse growth inhibition caused by FLC in C. neoformans. PDTC-mediated
growth recovery of C. neoformans and to a lesser extent
also AA-mediated growth recovery of C. neoformans, in the
presence of FLC, may require expression of metallothioneins, while for RA and GSH to exert their effects metallothioneins activity may not be critical.
Our data suggested that the degree to which the antioxidants reversed the inhibition by FLC was unequal.
One explanation of these differences may be the ability
of each antioxidant to reduce ROS at applied concentrations. To test this possibility, we examined the capacity
of each of the antioxidants to reduce ROS in C. neoformans. First, we utilized hydrogen peroxide, which is a
well-established ROS-generating agent that induces
oxidative stress in C. neformans cells, as determined by
increased expression of enzymatic antioxidants, including
CAT1, CAT3, and TRR1 [34]. We performed a growth
spot assay with the wild type (H99) strain in either YPD
media plates, YPD supplemented with 3 mM hydrogen
peroxide, or YPD supplemented with 3 mM hydrogen peroxide and one of the four antioxidants (AA, RA, PDTC, or
GSH). As shown in Fig. 3a, in the presence of 3 mM
hydrogen peroxide, growth of cells was dramatically reduced. Strikingly, the presence of 10 mM GSH or 10 mM
AA led to a complete rescue of growth from the inhibitory
effects of hydrogen peroxide, which indicates that AA and
GSH are potent antioxidants in C. neoformans. RA and
PDTC also rescued growth inhibition by hydrogen peroxide, but not to the same extent as GSH or AA (Fig. 3a).
These results were further confirmed by the disc diffusion
assay, in which wild type cells were plated on either YPD
or YPD media supplemented with an antioxidant (AA,
RA, GSH or PDTC) and exposed to a control disc and 3
discs with increasing concentrations of hydrogen peroxide
(25, 50, or 100 mM). As shown in Fig. 3b, in the absence
of an antioxidant, distinct zones of inhibition were formed
that increased in diameter, as the concentration of hydrogen peroxide increased. When YPD was supplemented
with the antioxidants GSH and AA, the diameters of the
zones of inhibition at all the concentrations of hydrogen
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Fig. 2 Metallothioneins contribute to antioxidant-mediated growth rescue in the presence of FLC. a Growth spot assay of wild type (H99), and
the cmt1Δ, cmt2Δ, cmt1/2Δ mutants on YPD, or YPD supplemented with FLC (32 μg/mL) or FLC and an antioxidant (10 mM PDTC, 1 mM RA, 10
mM AA, 10 mM GSH). b 2 × 106 of wild type cells (H99) or metallothionein mutants were spread on YPD semi-solid media or YPD media
supplemented with antioxidants at concentrations as described in a. Discs containing increasing amounts of FLC (25, 50, or 100 μg) were placed
on media and the growth inhibition zones were examined after 2 days of incubation at 25 °C. c Graph based on quantification of the results of
the experiment described in b (based on three replicates). Error bars indicate standard deviation. Stars indicate significant growth rescue by the
antioxidant as compared to the control treatment (p < 0.05)

peroxide tested were smaller. However, presence of PDTC
or RA in the YPD media did not lead to the reduction of
the zones of inhibition in the presence of hydrogen peroxide, indicating that AA and GSH were more effective antioxidants to alleviate the effects of hydrogen peroxide in C.
neoformans when compared to PDTC and RA. Thus, our
results suggest that although all the antioxidants could
rescue growth inhibition in the presence of hydrogen

peroxide, GSH and AA are more potent antioxidants than
RA and PDTC in C. neoformans.
To further test whether addition of the antioxidants (RA,
AA, PDTC, or GSH) could reverse oxidative stress that is
present during FLC treatment, we carried out a fluorescent
assay to detect Reactive Oxygen Species (ROS). We used a
ROS indicator, 4-Amino-5-methylamino-2′,7′-difluorofluorescein diacetate (H2DCFDA), which binds to free
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Fig. 3 Analysis of the antioxidant potential of the tested compounds. a Growth spot assay showing wild type (H99) cells incubated on either YPD
alone, YPD containing 3 mM of hydrogen peroxide (H2O2), or YPD containing 3 mM H2O2 and an antioxidant (10 μM PDTC, 1 mM RA, 10 mM AA,
or 10 mM GSH). b Disc diffusion assay represents resistance of wild type strain (H99) to increasing concentrations of H2O2 (25, 50, 100 mM). ~ 2 ×
106 of cells were spread over YPD plates containing no antioxidant, or 10 μM PDTC, 1 mM RA, 10 mM AA, or 10 mM GSH. All antioxidants rescued
growth in the presence of 3 mM H2O2 with AA and GSH having more visible effect as compared to PDTC and RA. c A fluorescence assay to
measure ROS in wild type strain (H99) was performed, wherein greater fluorescence indicates higher levels of ROS. There is an increase of ROS in
the presence of FLC (p < 0.01), and ROS is reduced in the presence of FLC and an antioxidant (p < 0.01, either 10 μM PDTC, 1 mM, RA, 10 mM AA,
or 10 mM GSH) as indicated by a star. d Fluorescence assay to measure ROS in wild type (H99) and in metallothionein mutant strains (cmt1Δ,
cmt2Δ, cmt1/2Δ) was performed where the cells were treated with 32 μg/mL FLC. A significance of the increase in ROS in the mutant as
compared to the wild type control is indicated by a star, based on three replicates (p < 0.05)

radicals within the cell and can be detected as a fluorescent signal at an excitation wavelength of 495 nm and
emission wavelength of 529 nm, as used in a recent study
[19]. As shown in Fig. 3c, treatment with FLC led to elevated ROS and co-treatment with either GSH, AA, RA, or
PDTC significantly lowered levels of ROS. While all antioxidants lowered ROS generated in the presence of FLC,
GSH and AA led to the most significant decrease in ROS,
while the effect of RA and PDTC was less pronounced.
Furthermore, GSH and AA appeared to lower ROS
significantly below the endogenous levels, while PDTC
and RA specifically led to a decrease of ROS generated upon addition of FLC.
Based on data implicating metallothioneins in counteracting the inhibitory effects of FLC, we hypothesized that
FLC treatment may lead to a more extensive accumulation
of ROS in the metallothionein mutants as compared to
the wild type. In order to test whether the ROS generated
by wild type (H99) cells was lower compared to metallothionein mutants (either cmt1Δ, cmt2Δ, or cmt1/2Δ), we
carried out fluorescence measurements using the dye
H2DCFDA. As shown in Fig. 3d, the overall ROS was
significantly higher in cmt2Δ and the cmt1/2Δ double
mutants as compared to the wild type. These results suggest that the CMT2 metallothionein protein contributes
to lowering ROS in C. neoformans during FLC treatment.

Discussion
The main aim of this study was to determine whether
treatment with various antioxidants could reverse
growth defects and morphological defects caused by
FLC treatment in C. neoformans. Previous studies have
implicated FLC to be involved in generation of ROS in
C. albicans [16–18] and in C. neoformans [19]. It has
been shown that AA can rescue growth inhibition
caused by FLC in C. neoformans [19]. It has been demonstrated that addition of AA leads to induction of
ERG11 gene expression to allow for increased ergosterol
production and this process is mediated by a transcription factor Upc2 [23, 24]. Hence, how AA reduces
growth inhibition caused by FLC remains unclear. The
effect of FLC on ROS in C. neoformans shown in the
study by Peng et al. appears insignificant compared to
the increase of ROS caused by another antifungal drug,
amphotericin B [19, 35]. Another azole drug, itraconazole, led to ROS formation and lipid peroxidation in a
sibling species C. gattii in the early stages of the treatment; this did not occur with fluconazole [36]. Therefore, the contribution of ROS in C. neoformans during
FLC treatment remains unclear. We reasoned that if
antioxidants indeed reverse oxidative stress generated by
ROS, then various antioxidants should rescue growth
inhibition of C. neoformans in the presence of FLC.
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While we found that all tested antioxidants (AA, RA,
PDTC, and GSH) could rescue growth inhibited by FLC
(using growth assays, spot assays and disc diffusion
assays to assess sensitivity to FLC), the rescue was not
uniform. If we consider a measure of growth rescue in
the presence of hydrogen peroxide as an indicator of the
antioxidant potential, AA and GSH were the most
efficient antioxidants in C. neoformans, while PDTC and
RA were less effective as antioxidants compared to AA
and GSH. Interestingly, while GSH was one of the more
potent antioxidants, based on the ability of GSH to
lower ROS caused by hydrogen peroxide and FLC, GSH
only moderately rescued growth inhibition by FLC. This
suggests that the antioxidants may be counteracting specific species of ROS not always matching ROS type that
is generated during oxidative stress in the presence of
FLC. A non-exclusive possibility is that the effects of the
antioxidants also involve changes in the expression of ergosterol pathway genes in addition to lowering ROS and
collectively contribute to the survival in the presence of
FLC. Future studies that would examine ergosterol levels
and measure global gene expression in the presence of
FLC and specific antioxidants will help to resolve these
uncertainties.
Interestingly, each of the antioxidants tested could
rescue morphological growth defects caused by FLC. C.
neoformans wild type (H99) strain treated with (FLC) at
32 μg/mL displayed multi-budded phenotype most likely
due to inability to perform cytokinesis. Our study revealed that all the antioxidants tested (AA, RA, PDTC,
and GSH) can rescue cells from cytokinesis defects
caused by FLC, but not all antioxidants could rescue
growth inhibition due to FLC to the same extent. This
result suggests that while cytokinesis defect may contribute to growth defect in FLC-treated cells, eliminating
this aberration is not sufficient to restore growth in the
presence of FLC.
Another evidence that FLC is contributing to an increase in ROS in C. neoformans is the involvement of
the metallothionein genes CMT1 and CMT2 in resisting
the inhibitory effects of FLC. Metallothionein proteins
are essential for sequestering copper levels, which are
upregulated during infection by C. neoformans [29]. Increased copper levels can induce ROS, hence during infection by C. neoformans, expression of CMT genes is crucial.
Previous studies have shown that mutants of C. neoformans, lacking cmt genes are more sensitive to FLC treatment [19]. Our results suggest that cells lacking Cmt2 or
both Cmt1 and Cmt2 proteins are more sensitive to FLC.
We also find that Cmt mutants are compromised in their
ability to recover C. neoformans cells from FLC treatment
when antioxidants are added. Interestingly, the extent to
which the mutants could be rescued when co-treated with
FLC and an antioxidant varied depending on the type of
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antioxidant. We find that Cmt proteins play an important
role in PDTC-based growth rescue in FLC-treated cells.
This further suggests that these antioxidants act through
various molecular mechanisms to facilitate rescue from
FLC-mediated cell growth inhibition. Future studies should
determine the effects of the antioxidants on gene expression in cells treated with FLC. Including Cmt mutants in
transcriptional profiling of C. neoformans during various
treatments would shed light on molecular mechanisms responsible for FLC resistance in C. neoformans.
The antioxidants we have tested in this study have been
shown to reverse damage caused by many types of free
radicals. PDTC has been shown to reverse oxidative damage and carbonylation of proteins by reversing HOClmediated oxidative stress [37]. RA has been implicated in
hydroxyl radical and lipid peroxide scavenging [38]. AA
has been shown to reverse oxidative stress mainly caused
by oxygen free radicals [39, 40]. GSH has been implied in
reversing oxidative stress generated by hydrogen peroxide
[41] and lipid peroxides [42]. Previous studies using C.
glabrata as a model have suggested that FLC causes an
increase in singlet oxygen and peroxide radicals and can
cause DNA damage and treatment of Candida with FLC
increased activity of enzymatic antioxidants, namely
superoxide dismutase (SOD) and glutathione peroxidase
(GPx) [16]. It is possible that reversal of ROS and growth
defects in the presence of AA and GSH in C. neoformans
is due to the quenching of singlet oxygen species and
hydrogen peroxide damage caused by FLC. In addition to
DNA damage, it is possible that protein oxidation and
carbonylation could be increased in the presence of FLC,
which would explain the role played by PDTC in reversing
FLC damage in C. neoformans. FLC has been shown to be
more potent in Candida species strains defective in superoxide dismutase and catalase activity [43]. Hence RA
could have restored FLC-mediated growth inhibition by
regulated SOD levels in the presence of FLC. Further
investigations should determine what specific forms of
free radicals are upregulated in the presence of FLC and
the extent of DNA and protein damage that could be
caused in the presence of FLC.

Conclusions
In summary, we conclude that one of the effects of FLC
treatment in C. neoformans is an increase in ROS. Furthermore, addition of antioxidants can partially rescue
growth of C. neoformans in the presence of FLC. However, our results point to a complex nature of the effects
of the antioxidants and suggest that various mechanisms
contribute to the antioxidant-mediated growth rescue.
The significance of this study is in understanding environmental conditions that can cause rescue of growth of
C. neoformans in the presence of FLC and potentially
development of resistance to FLC. While formation of
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aneuploid cells is associated with FLC resistance, recent
studies are revealing that counteracting ROS caused by
FLC in fungi could also contribute to resisting FLC
mode of action. Understanding how individual antioxidants could reverse ROS generated by FLC and tying
their effects to transcriptional profiling of genes that
get altered during co-treatment with FLC and antioxidants would uncover molecular mechanisms that potentially lead to FLC resistance in C. neoformans and other
pathogenic fungi.

containing either YPD media alone, YPD plus 32 μg/μL
FLC, and YPD plus 32 μg/μL FLC and an antioxidant,
namely, 10 μM PDTC, 1 mM RA, 10 mM AA, or 10 mM
GSH. Spot growth assays were performed with a 10-fold
serial dilution of cells such that 2 μL contained either 104,
103, 102, or 10 cells and were carefully spotted onto YPD
plates alone, YPD plus 32 μg/μL FLC, or YPD plus FLC
and individual antioxidants, as described above. For both
growth assays and spot assays, cells grew for 48 h at 25 °C
before recording the data.

Methods

Fluorescence assay to detect ROS

Reagents used

Cells were grown overnight at room temperature in 2 ml
liquid YPD medium with constant agitation, diluted to
an Optical Density OD600 = 0.1, and grown for an additional 4 h. Subsequently, the culture was diluted to 10,
000 cells/ml and the cultures were either grown as no
treatment control, treated with either 32 μg/ml FLC, or
32 μg/ml FLC and an antioxidant (either 10 μM PDTC,
1 mM, RA, 10 mM AA, or 10 mM GSH) for 12 h. To detect ROS, 10 μM of a fluorescent dye, H2DCFDA, was
added to each of the samples and incubated for 1 h in
the dark at 25 °C. A control set of each of the samples
were incubated without the fluorescent dye. 250 μL of
the sample were added to each well of a 96-well microplate. ROS was measured as fluorescence emitted by the
fluorescent dye, H2DCFDA, at an excitation wavelength
of 485 nm and an emission wavelength of 535 nm. The
fluorescence reading was measured and recorded as
Relative Fluorescence Units (RFU). From each reading of
the sample treated with H2DCFDA the reading obtained
from the sample without addition of H2DCFDA was
subtracted. Each treatment was made in triplicate. All
data points were computed using multifactorial ANOVA
and Tukey’s HSD post hoc test.

Ascorbic Acid or AA (Fisher Scientific, Cat No A61-25,
CAS 5081-7) was prepared from a stock of 1 M, and used
at 10 mM. A reduced form of glutathione or GSH (Alfa
Aesar, Cat No AAJ6216606, CAS 70-18-8) was prepared
from a stock of 0.5 M, and used at 10 mM. Pyrrolidinedithiocarbamate or PDTC (Cayman Chemicals, Cat No
20713, CAS 5108-96-3) was prepared from a stock of 10
mM, and used at 10 μM. Retinoic Acid or RA (Cayman
Chemical, Cat No 11017, CAS 302-79-4) was prepared
from a stock of 100 mM (dissolved in dimethyl sulfoxide
(DMSO)), and used at 1 mM. The fluorescent dye for
ROS assays, 4-Amino-5-methylamino-2′,7′-difluorofluorescein diacetate (H2DCFDA) (Sigma, Cat No D6883, CAS
4091-99-0), was dissolved in DMSO at a stock concentration of 100 mM and used at 10 μM. Fluconazole (Cayman
Chemical, Cat No 11594, CAS 86386-73-4) was dissolved
in DMSO as a 50 mg/ml stock and used at 32 μg/ml.
Hydrogen peroxide (Cat No H325-100) was obtained from
Fisher Scientific.
Strains and media

Cryptococcus neoformans var. grubii wild type (strain
H99 Stud) is the derivative of the original strain isolated
in 1978 by John Perfect at Duke University (ATCC 208821)
that has been passaged through a rabbit at that time. The
cmt1Δ, cmt2Δ, cmt1/2Δ deletion mutants isogenic to H99
(CMT1, CNAG_05549; CMT2, CNAG_00306) were kindly
provided by the laboratory of Dr. Lukasz Kozubowski,
Clemson University (the metallothionein mutants were originally obtained from Dr. Dennis J. Thiele, Duke University).
Cells were grown on YPD media: (1% yeast extract, 2%
peptone, 2% dextrose, 2% agar), supplemented with chemicals as indicated in the text.
Fluconazole sensitivity plate and spot growth assays

Either wild type, cmt1Δ, cmt2Δ or cmt1/2Δ were grown in
liquid YPD broth overnight for 16 h. All strains were diluted to an Optical Density of OD600 = 0.1 and refreshed
in YPD liquid media for 4 h and then counted using a
Neubauer Hemocytometer. For growth assays, ~ 10,000
cells in exponential growth phase were spread onto plates

Disk diffusion assay

C. neoformans strains (wild type H99, or mutants,
cmt1Δ, cmt2Δ, or cmt1/2Δ) were grown in 2 ml of YPD
liquid broth overnight, for 16 h, diluted to an OD600 =
0.1 and refreshed for 4 h. Each strain was counted using
a hemocytometer and ~ 2 × 106 cells were plated onto
YPD semi-solid media plates containing either no antioxidant (control), AA (10 mM), RA (1 mM), PDTC (10 μM)
or GSH (10 mM), and spread with sterile Dynarex cotton
tipped applicators at opposing 90° angles. The plates were
left to dry before application of cotton disks. After 10 min
of drying, 6.6 mm cotton disks were lightly placed perpendicular on top of the YPD medium as to not break the
surface of the gel. Depending on the experiment, either increasing amounts of 25, 50 and 100 micrograms of FLC,
or increasing concentrations of 25, 50, and 100 mM
hydrogen peroxide were added to the top end of the disk
in order for the FLC or hydrogen peroxide to diffuse

Dbouk et al. BMC Microbiology

(2019) 19:243

throughout the area surrounding the disc. Finally, the
discs were laid flush onto the medium equidistant from
one another. The cells grew for 48 h at 25 °C and all treatments were done in triplicate. Each zone of inhibition was
measured and the results from each of the three replicate
experiments were averaged. A multifactorial ANOVA
along with a Tukey’s HSD post hoc test was used to indicate significance.
Microscopy

Differential interference contrast (DIC) microscopy was
used to study C. neoformans cell morphology under various conditions. C. neoformans cells were grown for 16 h at
25 °C in YPD liquid media, diluted down to an OD600 =
0.1, and refreshed for 4 h. Cells were then grown with either no treatment (control cells), treatment with FLC alone
at 32 μg/ml, or FLC at 32 μg/ml and an antioxidant (10 μM
PDTC, 1 mM RA, 10 mM AA, or 10 mM GSH) for 16 h.
Cells were centrifuged at 3000 x g for 2 min and washed
with ice cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4). An agar trap was made to
capture yeast cells, by melting 0.8% agarose on a slide as a
thin section. Cells were placed in an agar trap, covered
with a coverslip and visualized by Zeiss Axiovert 200
inverted microscope (Carl zeiss, Inc., Thornwood, NY).
Statistical analyses

For all statistical analyses, the Shapiro Wilk Test was
used to test for normality, and afterward, the Bartlett
Test was used to test for equality of variance. Since both
conditions were met, a multifactorial ANOVA was performed. The Tukey HSD test was used to determine if
the relationship between the control group and variable
groups were statistically significant.
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